Markets

Ascendis Pharma Receives Positive Opinion From Committee For Medicinal Products For Human Use Of European Medicines Agency For Marketing Authorization Of TransCon CNP In EU To Treat Achondroplasia

Oct 16, 2026 · 08:31 AM ET· updated 2h ago

Ascendis Pharma A/S (NASDAQ:ASND) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending marketing authorization

Why It Matters

A medicine company got approval to sell a new drug in Europe. When a company gets permission to sell medicine, it means more money could come in.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

ASND225.50

-1.12 (-0.49%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.